Thomas J Saphner
Overview
Explore the profile of Thomas J Saphner including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
2591
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Michel A, Yi H, Amenta J, Collins N, Vaynrub A, Umakanth S, et al.
BMC Med Inform Decis Mak
. 2024 Sep;
24(1):272.
PMID: 39334347
Background: Women with high-risk breast lesions, such as atypical hyperplasia (AH) or lobular carcinoma in situ (LCIS), have a 4- to tenfold increased risk of breast cancer compared to women...
2.
Sparano J, Crager M, Gray R, Tang G, Hoag J, Baehner F, et al.
NEJM Evid
. 2024 Jul;
3(8):EVIDoa2300267.
PMID: 39041867
Background: The 21-gene recurrence score (RS) assay (Oncotype DX) is used to guide adjuvant chemotherapy use for patients with hormone receptor-positive, HER2 (human epidermal growth factor receptor 2)-negative, axillary node-negative...
3.
Mezzanotte-Sharpe J, ONeill A, Mayer I, Arteaga C, Yang X, Wagner L, et al.
Breast Cancer Res Treat
. 2024 Jul;
207(2):275-282.
PMID: 38967884
Background: In 2008, bevacizumab received accelerated Food and Drug Administration (FDA) approval for use in human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer (MBC). Based on the pre-clinical...
4.
Mezzanotte-Sharpe J, ONeill A, Mayer I, Arteaga C, Yang X, Wagner L, et al.
Res Sq
. 2024 May;
PMID: 38746356
Background: In 2008, bevacizumab received accelerated Food and Drug Administration (FDA) approval for use in human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer (MBC). Based on the preclinical...
5.
Wolff A, Somerfield M, Dowsett M, Hammond M, Hayes D, McShane L, et al.
Arch Pathol Lab Med
. 2023 Jun;
147(9):993-1000.
PMID: 37303228
Purpose.—: To update the American Society of Clinical Oncology-College of American Pathologists (ASCO-CAP) recommendations for human epidermal growth factor receptor 2 (HER2) testing in breast cancer. An Update Panel is...
6.
Wolff A, Somerfield M, Dowsett M, Hammond M, Hayes D, McShane L, et al.
J Clin Oncol
. 2023 Jun;
41(22):3867-3872.
PMID: 37284804
Purpose: To update ASCO-College of American Pathologists (CAP) recommendations for human epidermal growth factor receptor 2 (HER2) testing in breast cancer. The Panel is aware that a new generation of...
7.
Albain K, Gray R, Makower D, Faghih A, Hayes D, Geyer C, et al.
J Natl Cancer Inst
. 2020 Sep;
113(4):390-399.
PMID: 32986828
Background: Black race is associated with worse outcomes in early breast cancer. We evaluated clinicopathologic characteristics, the 21-gene recurrence score (RS), treatment delivered, and clinical outcomes by race and ethnicity...
8.
Sparano J, Gray R, Makower D, Albain K, Saphner T, Badve S, et al.
JAMA Oncol
. 2019 Oct;
6(3):367-374.
PMID: 31566680
Importance: A high 21-gene recurrence score (RS) by breast cancer assay is prognostic for distant recurrence of early breast cancer after local therapy and endocrine therapy alone, and for chemotherapy...
9.
Sparano J, Gray R, Ravdin P, Makower D, Pritchard K, Albain K, et al.
N Engl J Med
. 2019 Jun;
380(25):2395-2405.
PMID: 31157962
Background: The use of adjuvant chemotherapy in patients with breast cancer may be guided by clinicopathological factors and a score based on a 21-gene assay to determine the risk of...
10.
Sparano J, Gray R, Makower D, Pritchard K, Albain K, Hayes D, et al.
N Engl J Med
. 2018 Jun;
379(2):111-121.
PMID: 29860917
Background: The recurrence score based on the 21-gene breast cancer assay predicts chemotherapy benefit if it is high and a low risk of recurrence in the absence of chemotherapy if...